

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding multiple myeloma | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2053/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2053" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding multiple myeloma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding multiple myeloma.">
            <meta name="og:description" content="Read the latest article version by Binod Dhakal, Saulius Girnius, Parameswaran Hari, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9446">
            <meta name="article-id" content="8777">
            <meta name="dc.title" content="Recent advances in understanding multiple myeloma">
            <meta name="dc.description" content="There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both.">
            <meta name="dc.subject" content="Multiple Myeloma, treatment, monoclonal antibodies, diagnosis, ">
            <meta name="dc.creator" content="Dhakal, Binod">
            <meta name="dc.creator" content="Girnius, Saulius">
            <meta name="dc.creator" content="Hari, Parameswaran">
            <meta name="dc.date" content="2016/08/23">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.8777.1">
            <meta name="dc.source" content="F1000Research 2016 5:2053">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Multiple Myeloma ">
            <meta name="prism.keyword" content=" treatment ">
            <meta name="prism.keyword" content=" monoclonal antibodies ">
            <meta name="prism.keyword" content=" diagnosis ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/08/23">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2053">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.8777.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2053">
            <meta name="citation_title" content="Recent advances in understanding multiple myeloma">
            <meta name="citation_abstract" content="There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both.">
            <meta name="citation_description" content="There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both.">
            <meta name="citation_keywords" content="Multiple Myeloma, treatment, monoclonal antibodies, diagnosis, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Binod Dhakal">
            <meta name="citation_author_institution" content="Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA">
            <meta name="citation_author" content="Saulius Girnius">
            <meta name="citation_author_institution" content="Division of Hematology/Oncology, University of Cincinnati, Cincinnati, OH, USA">
            <meta name="citation_author" content="Parameswaran Hari">
            <meta name="citation_author_institution" content="Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA">
            <meta name="citation_publication_date" content="2016/08/23">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2053">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.8777.1">
            <meta name="citation_firstpage" content="2053">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2053/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2053.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9446 /> <input type=hidden id=articleId name=articleId value=8777 /> <input type=hidden id=xmlUrl value="/articles/5-2053/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2053-v1.xml"> <input type=hidden id=article_uuid value=44422cdb-b353-4c97-ad1a-f6554d56dc35 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding multiple myeloma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.8777.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.8777.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2053"
  },
  "headline": "Recent advances in understanding multiple myeloma",
  "datePublished": "2016-08-23T16:10:23",
  "dateModified": "2016-08-23T16:10:23",
  "author": [
    {
      "@type": "Person",
      "name": "Binod Dhakal"
    },    {
      "@type": "Person",
      "name": "Saulius Girnius"
    },    {
      "@type": "Person",
      "name": "Parameswaran Hari"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2053.html",
            "name": "Recent advances in understanding multiple myeloma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding multiple myeloma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9446 data-id=8777 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8777.1" data-recommended="" data-doi="10.12688/f1000research.8777.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2053/v1/pdf?article_uuid=44422cdb-b353-4c97-ad1a-f6554d56dc35" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-8777-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-8777-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-8777-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Dhakal B, Girnius S and Hari P. Recent advances in understanding multiple myeloma [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2053 (<a class=new-orange href="https://doi.org/10.12688/f1000research.8777.1" target=_blank>https://doi.org/10.12688/f1000research.8777.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-8777-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=8777 id=track-article-signin-8777 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8777?target=/articles/5-2053.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9446 /> <input name=articleId type=hidden value=8777 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding multiple myeloma</h1><span class=other-info> [version 1; peer review: 4 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Binod Dhakal<sup>1</sup>,&nbsp;</span><span class="">Saulius Girnius<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:phari@mcw.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Parameswaran Hari</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Binod Dhakal<sup>1</sup>,&nbsp;</span><span class="">Saulius Girnius<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:phari@mcw.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Parameswaran Hari</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 23 Aug 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.8777.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA<br/> <sup>2</sup> Division of Hematology/Oncology, University of Cincinnati, Cincinnati, OH, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16639-15770></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=15621-15772></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16637-15769></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16638-15771></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Multiple Myeloma, treatment, monoclonal antibodies, diagnosis, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Parameswaran Hari (<a href="mailto:phari@mcw.edu">phari@mcw.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Parameswaran Hari </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Dhakal B <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Dhakal B, Girnius S and Hari P. Recent advances in understanding multiple myeloma [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2053 (<a href="https://doi.org/10.12688/f1000research.8777.1" target=_blank>https://doi.org/10.12688/f1000research.8777.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 23 Aug 2016, <b>5</b>(F1000 Faculty Rev):2053 (<a href="https://doi.org/10.12688/f1000research.8777.1" target=_blank>https://doi.org/10.12688/f1000research.8777.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 23 Aug 2016, <b>5</b>(F1000 Faculty Rev):2053 (<a href="https://doi.org/10.12688/f1000research.8777.1" target=_blank>https://doi.org/10.12688/f1000research.8777.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e173>Introduction</h2><p class="" id=d38673e176>Multiple myeloma (MM) is a clonal expansion of malignant plasma cells resulting in end organ damage, including lytic bone lesions, anemia, renal failure, or hypercalcemia. Both the understanding of MM and its management have evolved rapidly over recent years. Concomitant with the increasing incidence of MM to almost 30,000 patients annually in the US, mortality has trended down in the last decade, resulting in an increased prevalence of MM<sup><a href="#ref-1">1</a></sup>. In 2015, four new drugs—the first two monoclonal antibodies and two oral agents—were approved by the US Food and Drug Administration (FDA). Importantly, these drugs have improved the outcomes in relapsed and heavily pre-treated patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e186>High-risk smoldering multiple myeloma</h2><p class="" id=d38673e189>Smoldering MM (SMM) was traditionally defined on the basis of laboratory criteria—monoclonal (M) protein level of more than 3 g/dl or a clonal marrow plasmacytosis of more than 10%—and the absence of end organ damage. The ability to identify persons with SMM who are likely to progress rapidly to symptomatic MM has led to the revision of the criteria that define treatment initiation. Ultra-high-risk SMM patients with an 80% risk of progression to MM in 2 years are now considered in the updated criteria to have MM requiring treatment<sup><a href="#ref-2">2</a></sup>. Currently, SMM is defined by the presence of serum M protein of at least 3 g/dl or 10 to 60% of clonal bone marrow plasma cells (or both) with no evidence of target organ damage, myeloma-defining events (MDEs), or amyloidosis<sup><a href="#ref-2">2</a></sup>. Patients with high-risk SMM have a 25% risk of progression to MM in 2 years, whereas those with low risk have a 5% risk per year<sup><a href="#ref-3">3</a></sup>. Multiple prognostic markers have been identified as surrogates for high-risk SMM<sup><a href="#ref-4">4</a>–<a href="#ref-9">9</a></sup>. Some of these include SMM with serum M protein of at least 3 g/dl, IgA isotype, involved/uninvolved free light chain ratio of at least 8 (but less than 100), bone marrow clonal plasma cells of 50 to 60%, t(4;14), del(17p), or 1q gain and Bence-Jones proteinuria. Management of high-risk SMM remains controversial after treatment with lenalidomide was shown to improve overall survival (OS) compared with a strategy of observation until target organ damage<sup><a href="#ref-10">10</a></sup>. It is possible that SMM represents a curable stage of disease wherein early intervention approaches with limited toxicity may be curative and delay or avoid end organ damage provided that treatment does not lead to the outgrowth of more resistant clones. When compared with symptomatic MM, high-risk SMM can achieve a deeper response, as measured by minimal residual disease (MRD), with 11 out of 12 patients developing MRD negativity<sup><a href="#ref-11">11</a></sup>. A longer follow-up is necessary to determine the duration of response, comparing it with the financial and physical burden of therapy. Thus, these treatments should be performed in clinical trials exploring the timing, the benefits, and the type of therapy in high-risk SMM.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e223>New criteria for multiple myeloma</h2><p class="" id=d38673e226>The revised International Myeloma Working Group criteria for the diagnosis of MM requires, in addition to the presence of either 10% or more clonal plasma cells or a biopsy-proven plasmacytoma, one or more MDEs. MDE includes CRAB features (increased calcium level, renal dysfunction, anemia, and destructive bone lesions) and three specific biomarkers: (a) clonal plasma cells of at least 60%, (b) involved/uninvolved light chain ratio of at least 100, and (c) more than one focal lesion on magnetic resonance imaging. Each of these biomarkers was associated with an 80% risk of progression to symptomatic MM in 2 years in independent studies<sup><a href="#ref-4">4</a>,<a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>.</p><p class="" id=d38673e239>Staging of MM was recently updated to reflect the advances in treatment of MM as well as improved detection of high-risk disease. Revised-International Staging System (R-ISS) stage I disease includes ISS stage I with a normal lactate dehydrogenase (LDH) level and absence of high-risk cytogenetics (del(17p), t(4;14), or t(14;16)). R-ISS III includes ISS stage III with either high-risk cytogenetics or elevated LDH. R-ISS II includes all others. The 5-year OS rates were 82% in R-ISS I, 62% in R-ISS II, and 40% in R-ISS III<sup><a href="#ref-12">12</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e249>Clonal dominance</h2><p class="" id=d38673e252>The initial event leading to malignant plasma cells occurs in the germinal center during isotype class switching and somatic hypermutation. These mutations are present in monoclonal gammopathies of unknown significance but are not sufficient for evolution to MM<sup><a href="#ref-13">13</a></sup>. The progression to MM involves additional oncogenic events, including activation of oncogenes <i>K-Ras</i>, <i>N-Ras</i>, <i>FAM46C</i>, <i>MYC</i>, and <i>BRAF</i> and loss of function of <i>p53</i>, epigenetic changes with histone methylation/deacetylation, and genomic instability<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. No one common driver mutation has been identified in MM, although recurrent variants have been identified. Deregulation of the RAS/MAPK, NF-κB pathway, and apoptotic response are involved, but only the inability for effective apoptotic response to DNA damage has prognostic value<sup><a href="#ref-15">15</a></sup>. A second study confirmed that the presence of the aforementioned oncogenes did not influence OS or progression-free survival (PFS)<sup><a href="#ref-16">16</a></sup>. In MM, at least four distinct evolutionary patterns can be discerned between initial treatment phase and subsequent relapses. The simplest situation is no change in the clonal and sub-clonal composition between various time points in the natural course of disease, which represents re-emergence of the original clonal plasma cell population at relapses. About one-third of patients in this group have stable genomes and are typically associated with hyperploidy and favorable outcomes. The other three scenarios include “either differential clonal response or clonal tides” where in sub-clones are identified at different time points, but their relative proportions change over time or linear clonal evolution where a new (previously undetectable) sub-clone emerges later or a branching evolution pattern corresponding to the emergence of new clones with the disappearance of old ones<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. In these three groups, selective therapeutic pressures can suppress responsive clones, allowing resistant clones to become dominant. Persons with high-risk disease are more likely to exhibit linear evolution or clonal tides. Clones with inherent genomic instability, detected at low levels at diagnosis, may undergo further genomic shifts when exposed to DNA-damaging agents, emerging after multiple relapses as the fatal clone. Understanding the clonal evolution pattern will become increasingly relevant as therapeutic choices expand in order to select appropriate treatment for patients. Re-emergence of a previously sensitive sub-clone would warrant the use of the same combination therapy at relapse. Alternatively, the emergence under treatment-induced selection pressure of a newly dominant linearly evolved or pre-existing resistant sub-clone should lead to alternate drugs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e303>Newer proteasome inhibitors</h2><p class="" id=d38673e306>Two new proteasome inhibitors (PIs) have been approved in recent years: carfilzomib (K) and ixazomib (I). Carfilzomib is an intravenous, irreversible PI with impressive outcomes in both newly diagnosed MM and relapsed MM. In patients with early relapse (one to three prior regimens), when compared with lenalidomide and dexamethasone (RD), carfilzomib in combination with lenalidomide and dexamethasone (KRD) improved PFS (hazard ratio (HR) 0.69, <i>P</i> = 0.0001) and OS (HR 0.79, <i>P</i> = 0.04)<sup><a href="#ref-18">18</a></sup>. In newly diagnosed patients, the KRD triplet had a response rate of 98%, a complete response rate of 56%, and MRD negativity rate by next-generation sequencing of 58%, and no discontinuation due to adverse events<sup><a href="#ref-11">11</a></sup>. Benefits of carfilzomib include rapid time to response, excellent tolerability (15% discontinued due to adverse events), efficacy in high-risk disease, and the low rate of carfilzomib-induced peripheral neuropathy. Challenges with carfilzomib include twice-weekly intravenous administration, the risk for tumor lysis syndrome, and the possibility for cardiac events and dyspnea. One retrospective study identified that more than 20% of patients developed systolic heart failure or arrhythmias. Previous irradiation to the thoracic spine and concomitant administration of doxorubicin increased the risk for cardiac dysfunction<sup><a href="#ref-19">19</a></sup>. To overcome these challenges, recent trials have demonstrated tolerability and response with escalated doses<sup><a href="#ref-20">20</a></sup>, whereas others are investigating efficacy of once-weekly dosing.</p><p class="" id=d38673e332>Ixazomib is an orally bioavailable, reversible PI with higher tissue distribution and a shorter dissociation half-life than bortezomib<sup><a href="#ref-21">21</a></sup>. It has modest single-agent activity and response to bortezomib-exposed persons when combined with dexamethasone<sup><a href="#ref-22">22</a></sup>. The combination of ixazomib with lenalidomide and dexamethasone (IRD) compared with RD shortened the time to response, improved the overall response rate, and increased median PFS (20.6 versus 14.7 months, HR 0.74, <i>P</i> = 0.012)<sup><a href="#ref-23">23</a></sup>. Early signal also suggests that it may overcome the negative impact of cytogenetic alterations. Major toxicities include gastrointestinal (GI) toxicity, peripheral neuropathy, and cyclical thrombocytopenia. The tissue distribution and dissociation half-life have a theoretical benefit with extramedullary disease, although this has not yet been demonstrated in a clinical trial. Ixazomib can be used as the proteasome backbone for combination oral therapies, reducing the need for frequent infusion visits. IRD is being investigated in newly diagnosed, transplant-ineligible persons with MM in a multi-center clinical trial, but results are not yet available. The availability of an oral PI also increases the feasibility of oral PI-based maintenance/consolidation regimens after transplant. Although it has been approved by the FDA, European regulators are waiting for additional positive data.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e354>Immunomodulatory drug</h2><p class="" id=d38673e357>Immunomodulatory drug (IMID) can bind cereblon on the E3 ubiquitin ligase complex, enhancing the ubiquitination and degradation of two zinc finger transcription factors<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. Pomalidomide is an oral third-generation IMID approved for relapsed refractory MM after at least two prior regimens. In lenalidomide-refractory patients, including 75% who were dual refractory, the response rate for pomalidomide and weekly dexamethasone was 30% with a 4-month PFS<sup><a href="#ref-26">26</a></sup>. In high-risk cytogenetics, patients with del(17p) had higher response rates, duration of response, and time to progression than those with t(4;14)<sup><a href="#ref-27">27</a></sup>. Pomalidomide is more effective earlier in the disease course<sup><a href="#ref-28">28</a></sup>, although approximately 40% of bortezomib- and lenalidomide-refractory patients can have a prolonged PFS<sup><a href="#ref-29">29</a></sup>. Toxicities, including cytopenias, rash, and peripheral neuropathy, are unpredictable<sup><a href="#ref-30">30</a></sup>. Unlike prior IMIDs, pomalidomide causes less endothelial stress and may be associated with lower rates of venous thromboembolic events, although patients should be on prophylactic anti-platelet therapy or anticoagulation<sup><a href="#ref-31">31</a></sup>. Its limited toxicity allows for combination with PIs, cyclophosphamide, and monoclonal antibodies, improving its efficacy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e395>Histone deacetylase inhibitor</h2><p class="" id=d38673e398>Panobinostat, a pan-histone deacetylase inhibitor (HDAC), targets HDAC enzymes involved in the aggresome protein degradation pathway, working synergistically with PIs. In a heavily pre-treated patient population, including 73% who were bortezomib-refractory, the response rate of panobinostat, bortezomib, and dexamethasone was 35% with a 5.4-month PFS<sup><a href="#ref-32">32</a></sup>. In bortezomib-refractory patients, the clinical benefit rate was better than 50% with a 4.2-month PFS. As high rates of GI distress and thrombocytopenia are seen with this agent, tolerability is a major impediment to its use and requires intense clinic/nursing support for continuous use. Dose interruptions occur in more than 50%, and relative dose intensity is only 73%. In a less heavily pre-treated population, response rates and PFS are improved, but the difficulty in maintaining dose intensity persists<sup><a href="#ref-33">33</a></sup>. Nonetheless, panobinostat has a novel mechanism of action, is an oral agent, and continues to have an important role in the management of MM, especially in the PI-refractory setting.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e412>Monoclonal antibody</h2><p class="" id=d38673e415>The FDA has recently approved two monoclonal antibodies in relapsed or refractory MM (RRMM) or both—elotuzumab and daratumumab—which target the signaling lymphocytic activation molecule F7 (SLAMF7) and CD38, respectively<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. In a phase III trial of patients with RRMM, the addition of elotuzumab to RD significantly improved PFS (19.4 versus 14.9 months, <i>P</i> &lt; 0.001)<sup><a href="#ref-35">35</a></sup>. In addition, it improves the PFS of the subsequent therapy, suggesting a lasting effect on natural killer (NK) cells. Single-agent daratumumab produced a response rate of approximately 30% in heavily pre-treated patients and little toxicity other than infusion reactions<sup><a href="#ref-34">34</a></sup>. Another CD38 antibody, isatuximab (SAR650984), has shown similar single-agent activity in RRMM but is not commercially available<sup><a href="#ref-36">36</a></sup>. Both elotuzumab and daratumumab are being investigated in the front-line setting, and given the unprecedented single-agent activity, it is likely that daratumumab might be the backbone of MM treatment, akin to rituximab in B-cell lymphomas. Emerging data point to impressive responses for anti-CD38 antibodies in combination with IMIDs and PIs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e443>Triplets at induction</h2><p class="" id=d38673e446>When compared with doublets, triplet induction therapy containing a PI and an IMID results in a higher response rate and improved PFS and is preferred whenever possible in fit patients, especially given the synergism between these two drug classes<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. A recent study has shown that bortezomib-lenalidomide and dexamethasone (VRD) has superior OS compared with RD<sup><a href="#ref-39">39</a></sup>. Bortezomib-thalidomide and dexamethasone (VTD) has shown superior response rates than thalidomide and dexamethasone (TD) and bortezomib-dexamethasone in randomized trials<sup><a href="#ref-37">37</a></sup>. Bortezomib-cyclophosphamide and dexamethasone (VCD) was recently shown to have lower response rates than VTD<sup><a href="#ref-40">40</a></sup> (<a href="#T1">Table 1</a>). Although greater hematologic toxicity is seen in the former and peripheral neuropathy in the latter, the overall rate of grade 3/4 toxicity is similar, and individualization of therapy should dictate treatment decisions<sup><a href="#ref-41">41</a></sup>. The second-generation PI carfilzomib in combination with lenalidomide and dexamethasone (KRD) has also shown excellent response rates in phase II trials<sup><a href="#ref-42">42</a></sup>, but additional data and regulatory approval are necessary prior to broader use. Conversely, lenalidomide-based triplets failed to show a PFS or OS benefit over lenalidomide-based doublets in an elderly population<sup><a href="#ref-43">43</a></sup>. When compared with doublets, triplet therapies are associated with increased toxicity and usually longer PFS but not necessarily OS. The upfront use of the most active agents may limit treatment choices in future lines of therapy, possibly shortening the second and subsequent PFS periods. Given the prolonged survival in patients with myeloma as well as rapidly changing treatment modalities, this debate may be difficult to resolve.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Triplet induction regimens and autologous stem cell transplantation studies in newly diagnosed multiple myeloma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d38673e495 class=n-a></a><thead><a name=d38673e497 class=n-a></a><tr><a name=d38673e499 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d38673e501 class=n-a></a>Regimen</th><th align=left colspan=1 rowspan=1><a name=d38673e504 class=n-a></a>Number of<br class=br>patients</th><th align=left colspan=1 rowspan=1><a name=d38673e509 class=n-a></a>Overall response<br class=br>rate</th><th align=left colspan=1 rowspan=1><a name=d38673e514 class=n-a></a>PFS</th><th align=left colspan=1 rowspan=1><a name=d38673e517 class=n-a></a>OS</th><th align=left colspan=1 rowspan=1><a name=d38673e521 class=n-a></a>Comments</th></tr></thead><tbody><a name=d38673e526 class=n-a></a><tr><a name=d38673e528 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d38673e530 class=n-a></a>VTD vs. TD<sup><a href="#ref-38">38</a></sup></td><td align=left colspan=1 rowspan=1><a name=d38673e536 class=n-a></a>241 vs. 239</td><td align=left colspan=1 rowspan=1><a name=d38673e539 class=n-a></a>31% vs. 11%</td><td align=left colspan=1 rowspan=1><a name=d38673e542 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1><a name=d38673e545 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1><a name=d38673e549 class=n-a></a>NR</td></tr><tr><a name=d38673e553 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d38673e555 class=n-a></a>VTD vs. VCD<sup><a href="#ref-42">42</a></sup></td><td align=left colspan=1 rowspan=1><a name=d38673e561 class=n-a></a>170 vs. 170</td><td align=left colspan=1 rowspan=1><a name=d38673e564 class=n-a></a>92.3% vs. 83.4%</td><td align=left colspan=1 rowspan=1><a name=d38673e567 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1><a name=d38673e570 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1><a name=d38673e574 class=n-a></a>NR</td></tr><tr><a name=d38673e578 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d38673e580 class=n-a></a>VRD vs. RD<sup><a href="#ref-40">40</a></sup></td><td align=left colspan=1 rowspan=1><a name=d38673e586 class=n-a></a>242 vs. 232</td><td align=left colspan=1 rowspan=1><a name=d38673e589 class=n-a></a>71% vs. 63%</td><td align=left colspan=1 rowspan=1><a name=d38673e592 class=n-a></a>43 vs. 31 months</td><td align=left colspan=1 rowspan=1><a name=d38673e595 class=n-a></a>NR vs. 63 months</td><td align=left colspan=1 rowspan=1><a name=d38673e599 class=n-a></a>Median OS/PFS</td></tr><tr><a name=d38673e603 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d38673e605 class=n-a></a>Conventional chemo<br class=br>vs. ASCT<sup><a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1><a name=d38673e613 class=n-a></a>100 vs. 100</td><td align=left colspan=1 rowspan=1><a name=d38673e616 class=n-a></a>81% vs. 22%</td><td align=left colspan=1 rowspan=1><a name=d38673e619 class=n-a></a>28% vs. 10%</td><td align=left colspan=1 rowspan=1><a name=d38673e622 class=n-a></a>52% vs. 12%</td><td align=left colspan=1 rowspan=1><a name=d38673e626 class=n-a></a>Pre-novel era;<br class=br>5-year OS/PFS</td></tr><tr><a name=d38673e632 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d38673e634 class=n-a></a>ASCT vs. MPR<sup><a href="#ref-57">57</a></sup></td><td align=left colspan=1 rowspan=1><a name=d38673e640 class=n-a></a>141 vs. 132</td><td align=left colspan=1 rowspan=1><a name=d38673e643 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1><a name=d38673e646 class=n-a></a>54.7 vs. 37.4 months</td><td align=left colspan=1 rowspan=1><a name=d38673e649 class=n-a></a>78.6% vs. 66.6%</td><td align=left colspan=1 rowspan=1><a name=d38673e653 class=n-a></a>Novel era<br class=br>PFS (median)<br class=br>OS (5-year)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d38673e665 class=n-a></a><p id=d38673e667> ASCT, autologous stem cell transplantation; MPR, melphalan/prednisone and revlimid; NR, not reported; OS, overall survival; PFS, progression-free survival; RD, lenalidomide and dexamethasone; TD, thalidomide and dexamethasone; VCD, bortezomib-cyclophosphamide and dexamethasone; VRD, bortezomib-lenalidomide and dexamethasone; VTD, bortezomib-thalidomide and dexamethasone.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e676>Triplets at first relapse</h2><p class="" id=d38673e679>Management of RRMM remains controversial, although the field is moving toward combination triplet therapy at first relapse in fit patients. In the US, an abundance of second-line therapies are available, allowing individualization of therapy to both the patient and the disease. In older persons with RRMM, a geriatric assessment should be performed to determine a frailty score, evaluating the Katz Activities of Daily Living, the Lawton Instrumental Activity of Daily Living, and the Charlson Comorbidity Index<sup><a href="#ref-44">44</a></sup>. Frail patients have shorter OS irrespectively of staging, treatment types, or physician-assessed performance status. Even when adjusted for International Staging System and chromosomal abnormalities, frail patients have shorter OS and PFS and higher rates of non-hematologic adverse events and treatment discontinuation and are likely to benefit from dose-adjusted therapy. Other validated frailty indexes evaluate similar factors as well as cytogenetics, renal function, and Karnofsky Performance Status<sup><a href="#ref-45">45</a></sup>.</p><p class="" id=d38673e690>The addition of a third drug to an IMID steroid combination improves response rates and PFS, although an OS benefit is not demonstrated consistently<sup><a href="#ref-18">18</a>,<a href="#ref-35">35</a>,<a href="#ref-46">46</a></sup>. The addition of bortezomib (intravenous) to TD prolongs time to progression (HR 0.59, <i>P</i> = 0.001) in previously transplanted patients and results in a trend toward improved 24-month survival (71% versus 65%, <i>P</i> = 0.093)<sup><a href="#ref-46">46</a></sup>. However, this population is not typical for the US, since only 20% were previously treated with bortezomib and 8% with thalidomide. Although VTD may have a limited role in the US, this study does illustrate the benefit of triplet therapy. The addition of carfilzomib to lenalidomide and dexamethasone improves not only response rates and PFS (HR 0.069, <i>P</i> = 0.0001) but also 24-month survival (HR 0.79, <i>P</i> = 0.04)<sup><a href="#ref-11">11</a></sup>. The data from other recent trials of triplets in early relapsed disease, though clearly demonstrating PFS benefit, did not show an OS advantage.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e727>Which triplet to use</h2><p class="" id=d38673e730>The choice of treatment at relapse is determined by the type, response, and duration of initial therapy as well as disease factors, patient factors, and patient preference. The ideal sequence of therapies is not known, but switching drug classes is likely beneficial, especially in higher-risk disease, given the evidence for clonal tides. For instance, if there is disease progression while on lenalidomide maintenance, a triplet containing lenalidomide would likely provide a suboptimal response. If available, carfilzomib/IMID triplet should be considered in aggressive relapses, given the excellent data with rapid induction of response and high rates of MRD negativity. Those who relapse following a short duration of remission after upfront therapy, including autologous stem cell transplant, or symptomatic relapses with significant clinical symptoms or disease relapse in high-risk cytogenetics are generally considered to be aggressive relapses. Elotuzumab-based treatment could be considered in individuals who are frail or have underlying cytopenias. An ixazomib-based regimen is an option if an oral regimen is desired and, based on early trends, may be considered, especially in del(17p) or extramedullary disease. A pomalidomide-based regimen could also be considered in del(17p). Panobinostat has a limited role in first relapse because of the toxicity profile unless used to restore PI sensitivity in those relapsing after prior PI regimens.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e737>Transplant still better</h2><p class="" id=d38673e740>High-dose therapy followed by autologous stem cell transplantation (ASCT) was the standard of care for transplant-eligible patients before the era of novel agents. In pre-novel agent randomized trials, ASCT was uniformly associated with improved response rates and PFS, and about half of the studies showed an OS benefit and superior quality of life<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. In one of the studies designed to address the question of early versus late ASCT<sup><a href="#ref-49">49</a></sup>, patients undergoing ASCT were found to have longer time without symptoms and treatment, and thus the patients with ASCT were found to have improved quality of life.</p><p class="" id=d38673e754>Given the unprecedented response rates with novel agents, the role of ASCT as front-line therapy has been questioned<sup><a href="#ref-50">50</a>–<a href="#ref-52">52</a></sup>. Novel agents have significantly improved the rate of complete response and MRD, both surrogates for improved survival<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. The early versus late ASCT was investigated in a number of randomized trials<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>, most recently in an international study conducted in the context of modern therapy with VRD induction, ASCT, and lenalidomide maintenance<sup><a href="#ref-57">57</a></sup>. Superior OS benefit was seen in one study<sup><a href="#ref-56">56</a></sup> whereas in the other two studies, early ASCT was found to have better PFS with no transplant-related deaths<sup><a href="#ref-55">55</a>,<a href="#ref-57">57</a></sup>. Maintenance therapy after ASCT is gaining increased acceptance. Two randomized trials demonstrated a PFS benefit to lenalidomide maintenance, but only the Cancer and Leukemia Group B (CALGB) trial demonstrated an OS benefit<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. The difference in results could be explained by the use of two cycles of consolidation chemotherapy after ASCT and only one year of maintenance lenalidomide in the IFM (Intergroupe Francophone du Myelome) trial. In addition, the majority of subjects in the CALGB study, unlike the IFM trial, received a lenalidomide-based induction regimen. In addition, an unplanned subset analysis in the CALGB trial failed to show an OS benefit in those who did not receive a lenalidomide-based induction regimen. Likewise, bortezomib maintenance can improve PFS and possibly OS<sup><a href="#ref-60">60</a></sup>. Further support for maintenance comes from the observation that maintenance lenalidomide, despite ASCT and consolidation therapy, can further deepen response, when measuring for MRD by flow<sup><a href="#ref-61">61</a></sup>. Last, newer data demonstrate the benefit to continuous therapy. A meta-analysis of three trials, one of which included ASCT as part of consolidation, demonstrated improved PFS1, PFS2 (time to second progression of death), and OS with continuous therapy. In fact, a prolonged PFS1 did not reduce PFS2<sup><a href="#ref-62">62</a></sup>. In conclusion, novel agent-based triplet induction, front-line early ASCT, and maintenance therapy remain the preferred strategy for transplant-eligible patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e816>Immunotherapy</h2><p class="" id=d38673e819>The best-established immunotherapy in MM is allogeneic transplantation with a potent and often sustained graft-versus-myeloma (GVM) effect<sup><a href="#ref-63">63</a></sup>. A series of prospective randomized studies, both in the US and Europe, explored the role of a tandem ASCT and reduced-intensity conditioning allogeneic stem cell transplants from a matched sibling or unrelated donor<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. The results of these studies have been discordant, especially in the front-line treatment of MM<sup><a href="#ref-65">65</a>–<a href="#ref-68">68</a></sup>. Nonetheless, younger eligible patients with well-defined high-risk features should be considered for allogeneic transplant, especially within a clinical trial and early in the clinical course (front-line or first relapse). The risks of chronic graft-versus-host disease (cGVHD) and the need for long-term immunosuppression remain major challenges. A number of studies suggest that immune therapy works in MM and these include demonstration of clinically meaningful GVM effect by donor lymphocyte infusions in patients relapsing after allogeneic transplant<sup><a href="#ref-69">69</a></sup>, complete remission after immunosuppression withdrawal<sup><a href="#ref-62">62</a></sup>, progression after allogeneic transplant, and the presence of cGVHD correlating with freedom from progression after allogeneic transplant<sup><a href="#ref-64">64</a></sup>.</p><p class="" id=d38673e853>A variety of novel post-ASCT or allogeneic transplant immunotherapeutic strategies are now being explored in MM. These include cellular approaches such as myeloma-specific T cells (via T-cell expansion), marrow-infiltrating lymphocytes<sup><a href="#ref-70">70</a></sup>, redirected T cells with chimeric antigen receptors<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>, and tumor-based vaccines to induce myeloma-specific immunity in the context of enhanced antigen presentation<sup><a href="#ref-73">73</a></sup>. A phase I/II study showed that adoptive transfer of tumor antigen vaccine-primed and co-stimulated T cells leads to augmented and accelerated cellular and humoral immune reconstitution, including antitumor immunity, after ASCT<sup><a href="#ref-74">74</a></sup>. In another phase II trial, idiotype-pulsed antigen-presenting cells immunotherapeutic called APC8020 (Mylovenge), which was given after ASCT for MM, appeared to be associated with improved OS<sup><a href="#ref-75">75</a></sup>. In a recent report, deep sustained response to anti-CD19 chimeric antigen receptor T cells was reported in a patient with relapsed/refractory disease<sup><a href="#ref-76">76</a></sup>. Several promising antigenic targets have been identified for the development of anti-MM chimeric antigen receptors, such as B-cell maturation antigen, CD138, kappa light chains, and CS-1. Inhibitors of PD-1 and PDL-1 are being studied as a means of breaking down MM immune tolerance<sup><a href="#ref-71">71</a>,<a href="#ref-77">77</a></sup>. Though the anti-PD1 agent nivolumab was unimpressive<sup><a href="#ref-78">78</a></sup>, promising response rates were observed in combination with lenalidomide<sup><a href="#ref-79">79</a></sup>. NK cell therapy has generated interest in the treatment of MM and a number of studies are exploring this option. These include modulation of NK activity using anti-KIR Ab IPH2101 (monoclonal antibody against inhibitory KIR on NK cells) to establish MM-specific immunity<sup><a href="#ref-80">80</a></sup> safety and efficacy study of autologous-, allogeneic-, and cord-derived NK cells<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>. A clinical trial involving the haploidentical allo-stem cell transplant followed by planned NK cell infusion attempts to use donor-recipient KIR ligand mismatch and NK cell reactivity to facilitate long-term remission (NCT02100891). Another promising area is the use of tumor vaccine based on the study in which patients receiving a patient-specific dendritic cell/myeloma fusion vaccine demonstrated the expansion of MM-specific T cells as well as upgrading of response in a subgroup of patients<sup><a href="#ref-73">73</a></sup>. A randomized phase II trial (BMT CTN 1401) with ASCT followed by lenalidomide maintenance with or without vaccination using the dendritic cell/myeloma fusion vaccine is currently accruing patients.</p><p class="" id=d38673e915>Hematopoietic cell transplantation provides an ideal platform for additional immune-based therapies. The recovery phase from ASCT (or other lymphodepleting therapy) represents a favorable platform for adoptive cellular therapy. The homeostatic lymphocyte proliferation following lymphopenia is a context in which immune checkpoint blockers may also be able to reverse MM-associated T-cell exhaustion<sup><a href="#ref-71">71</a>,<a href="#ref-79">79</a></sup>. Additionally, lymphopenia resulting from ASCT facilitates elimination of tolerogenic antigen-presenting cells and induces cytokine release that generates a more favorable environment for adoptive T-cell therapy. Indirect evidence suggests that the immune system can contribute to the clinical benefits of ASCT (for example, those with early lymphoid recovery after ASCT have superior long-term outcomes)<sup><a href="#ref-83">83</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d38673e932>Conclusions</h2><p class="" id=d38673e935>Although MM has always been considered incurable, many investigators now believe that a significant fraction of patients currently undergoing therapy may be cured<sup><a href="#ref-84">84</a></sup>. It is clear that with the improved understanding of disease biology and clonal architecture of relapse, combined with the availability of multi-targeted approaches, we are closer to a lasting cure than ever before. Nonetheless, many questions remain unanswered. Will the better understanding of myeloma biology guide the intensity of treatment, with high-risk disease necessitating aggressive therapy? With an increasing number of drug classes as well as new drugs in each class, the combination and sequencing of drugs are largely unresolved.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d38673e1 class=n-a></a><h2 class=main-title id=d38963>Competing interests</h2><p class=metadata-entry><a name=d38673e110 class=n-a></a><p id=d38673e111> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d38673e1 class=n-a></a><h2 class=main-title id=d38965>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d38673e946 class=n-a></a><h2 class=main-title id=d38673e948>Acknowledgment</h2><p class="" id=d38673e951>We thank Monika Englehardt for the careful critical review of the manuscript.</p></div><div class=back-section><a name=d38673e955 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d39243>References</h2><div class="section ref-list"><a name=d38673e955 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d38673e962 class=n-a></a>Howlader N, Noone AM, Krapcho M, <i> et al.</i>: SEER Cancer Statistics Review (CSR) 1975–2013. National Cancer Institute. Bethesda, MD; 4/2016. <a target=xrefwindow id=d38673e967 href="http://seer.cancer.gov/csr/1975_2013/">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725258407"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e976 class=n-a></a>Rajkumar SV, Dimopoulos MA, Palumbo A, <i> et al.</i>: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncol.</i> 2014; <b>15</b>(12): e538–48. <a target=xrefwindow id=d38673e987 href="http://www.ncbi.nlm.nih.gov/pubmed/25439696">PubMed Abstract </a> | <a target=xrefwindow id=d38673e990 href="http://dx.doi.org/10.1016/S1470-2045(14)70442-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725258407">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725419665"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1003 class=n-a></a>Rajkumar SV, Landgren O, Mateos MV: Smoldering multiple myeloma. <i>Blood.</i> 2015; <b>125</b>(20): 3069–75. <a target=xrefwindow id=d38673e1011 href="http://www.ncbi.nlm.nih.gov/pubmed/25838344">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1014 href="http://dx.doi.org/10.1182/blood-2014-09-568899">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4432003">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725419665">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d38673e1030 class=n-a></a>Rajkumar SV, Gupta V, Fonseca R, <i> et al.</i>: Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. <i>Leukemia.</i> 2013; <b>27</b>(8): 1738–44. <a target=xrefwindow id=d38673e1041 href="http://www.ncbi.nlm.nih.gov/pubmed/23515097">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1044 href="http://dx.doi.org/10.1038/leu.2013.86">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1048 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3773463">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d38673e1057 class=n-a></a>Neben K, Jauch A, Hielscher T, <i> et al.</i>: Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. <i>J Clin Oncol.</i> 2013; <b>31</b>(34): 4325–32. <a target=xrefwindow id=d38673e1068 href="http://www.ncbi.nlm.nih.gov/pubmed/24145347">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1071 href="http://dx.doi.org/10.1200/JCO.2012.48.4923">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1087559"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1081 class=n-a></a>Kyle RA, Remstein ED, Therneau TM, <i> et al.</i>: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. <i>N Engl J Med.</i> 2007; <b>356</b>(25): 2582–90. <a target=xrefwindow id=d38673e1092 href="http://www.ncbi.nlm.nih.gov/pubmed/17582068">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1095 href="http://dx.doi.org/10.1056/NEJMoa070389">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1087559">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/5003957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1108 class=n-a></a>Hillengass J, Fechtner K, Weber MA, <i> et al.</i>: Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. <i>J Clin Oncol.</i> 2010; <b>28</b>(9): 1606–10. <a target=xrefwindow id=d38673e1119 href="http://www.ncbi.nlm.nih.gov/pubmed/20177023">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1122 href="http://dx.doi.org/10.1200/JCO.2009.25.5356">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/5003957">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1097745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1135 class=n-a></a>Dispenzieri A, Kyle RA, Katzmann JA, <i> et al.</i>: Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. <i>Blood.</i> 2008; <b>111</b>(2): 785–9. <a target=xrefwindow id=d38673e1146 href="http://www.ncbi.nlm.nih.gov/pubmed/17942755">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1149 href="http://dx.doi.org/10.1182/blood-2007-08-108357">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1153 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2200851">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1097745">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726326084"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1166 class=n-a></a>González-Calle V, Dávila J, Escalante F, <i> et al.</i>: Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia.</i> 2016. <a target=xrefwindow id=d38673e1174 href="http://www.ncbi.nlm.nih.gov/pubmed/27133826">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1177 href="http://dx.doi.org/10.1038/leu.2016.123">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726326084">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718056499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1190 class=n-a></a>Mateos MV, Hernández MT, Giraldo P, <i> et al.</i>: Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. <i>N Engl J Med.</i> 2013; <b>369</b>(5): 438–47. <a target=xrefwindow id=d38673e1201 href="http://www.ncbi.nlm.nih.gov/pubmed/23902483">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1204 href="http://dx.doi.org/10.1056/NEJMoa1300439">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718056499">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725646854"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1217 class=n-a></a>Korde N, Roschewski M, Zingone A, <i> et al.</i>: Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncol.</i> 2015; <b>1</b>(6): 746–54. <a target=xrefwindow id=d38673e1228 href="http://www.ncbi.nlm.nih.gov/pubmed/26181891">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1231 href="http://dx.doi.org/10.1001/jamaoncol.2015.2010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725646854">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d38673e1245 class=n-a></a>Palumbo A, Avet-Loiseau H, Oliva S, <i> et al.</i>: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>J Clin Oncol. </i> 2015; <b>33</b>(26): 2863–9. <a target=xrefwindow id=d38673e1256 href="http://www.ncbi.nlm.nih.gov/pubmed/26240224">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1259 href="http://dx.doi.org/10.1200/JCO.2015.61.2267">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1263 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4846284">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d38673e1272 class=n-a></a>Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. <i>Nat Rev Cancer.</i> 2012; <b>12</b>(5): 335–48. <a target=xrefwindow id=d38673e1280 href="http://www.ncbi.nlm.nih.gov/pubmed/22495321">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1283 href="http://dx.doi.org/10.1038/nrc3257">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d38673e1292 class=n-a></a>Bianchi G, Munshi NC: Pathogenesis beyond the cancer clone(s) in multiple myeloma. <i>Blood.</i> 2015; <b>125</b>(20): 3049–58. <a target=xrefwindow id=d38673e1300 href="http://www.ncbi.nlm.nih.gov/pubmed/25838343">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1303 href="http://dx.doi.org/10.1182/blood-2014-11-568881">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1306 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4432002">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725726310"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1315 class=n-a></a>Walker BA, Boyle EM, Wardell CP, <i> et al.</i>: Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. <i>J Clin Oncol.</i> 2015; <b>33</b>(33): 3911–20. <a target=xrefwindow id=d38673e1326 href="http://www.ncbi.nlm.nih.gov/pubmed/26282654">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1329 href="http://dx.doi.org/10.1200/JCO.2014.59.1503">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725726310">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718240585"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1342 class=n-a></a>Bolli N, Avet-Loiseau H, Wedge DC, <i> et al.</i>: Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nat Commun.</i> 2014; <b>5</b>: 2997. <a target=xrefwindow id=d38673e1353 href="http://www.ncbi.nlm.nih.gov/pubmed/24429703">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1356 href="http://dx.doi.org/10.1038/ncomms3997">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1360 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3905727">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718240585">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718016033"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1373 class=n-a></a>Keats JJ, Chesi M, Egan JB, <i> et al.</i>: Clonal competition with alternating dominance in multiple myeloma. <i>Blood.</i> 2012; <b>120</b>(5): 1067–76. <a target=xrefwindow id=d38673e1384 href="http://www.ncbi.nlm.nih.gov/pubmed/22498740">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1387 href="http://dx.doi.org/10.1182/blood-2012-01-405985">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1391 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3412330">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718016033">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725267926"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1405 class=n-a></a>Stewart AK, Rajkumar SV, Dimopoulos MA, <i> et al.</i>: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med.</i> 2015; <b>372</b>(2): 142–52. <a target=xrefwindow id=d38673e1416 href="http://www.ncbi.nlm.nih.gov/pubmed/25482145">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1419 href="http://dx.doi.org/10.1056/NEJMoa1411321">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725267926">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725765970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1432 class=n-a></a>Danhof S, Schreder M, Rasche L, <i> et al.</i>: ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. <i>Eur J Haematol.</i> 2016; <b>97</b>(1): 25–32. <a target=xrefwindow id=d38673e1443 href="http://www.ncbi.nlm.nih.gov/pubmed/26331915">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1446 href="http://dx.doi.org/10.1111/ejh.12677">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725765970">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718467625"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1459 class=n-a></a>Lendvai N, Hilden P, Devlin S, <i> et al.</i>: A phase 2 single-center study of carfilzomib 56 mg/m<sup>2</sup> with or without low-dose dexamethasone in relapsed multiple myeloma. <i>Blood.</i> 2014; <b>124</b>(6): 899–906. <a target=xrefwindow id=d38673e1473 href="http://www.ncbi.nlm.nih.gov/pubmed/24963043">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1477 href="http://dx.doi.org/10.1182/blood-2014-02-556308">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1480 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4624439">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718467625">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d38673e1493 class=n-a></a>Kupperman E, Lee EC, Cao Y, <i> et al.</i>: Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. <i>Cancer Res.</i> 2010; <b>70</b>(5): 1970–80. <a target=xrefwindow id=d38673e1504 href="http://www.ncbi.nlm.nih.gov/pubmed/20160034">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1507 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-2766">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725722564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1516 class=n-a></a>Kumar SK, LaPlant B, Roy V, <i> et al.</i>: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. <i>Blood Cancer J.</i> 2015; <b>5</b>: e338. <a target=xrefwindow id=d38673e1527 href="http://www.ncbi.nlm.nih.gov/pubmed/26275080">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1530 href="http://dx.doi.org/10.1038/bcj.2015.60">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4558585">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725722564">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726316640"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1547 class=n-a></a>Moreau P, Masszi T, Grzasko N, <i> et al.</i>: Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>N Engl J Med.</i> 2016; <b>374</b>(17): 1621–34. <a target=xrefwindow id=d38673e1558 href="http://www.ncbi.nlm.nih.gov/pubmed/27119237">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1561 href="http://dx.doi.org/10.1056/NEJMoa1516282">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726316640">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718194538"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1575 class=n-a></a>Lu G, Middleton RE, Sun H, <i> et al.</i>: The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. <i>Science.</i> 2014; <b>343</b>(6168): 305–9. <a target=xrefwindow id=d38673e1586 href="http://www.ncbi.nlm.nih.gov/pubmed/24292623">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1589 href="http://dx.doi.org/10.1126/science.1244917">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4070318">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718194538">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718194536"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1606 class=n-a></a>Krönke J, Udeshi ND, Narla A, <i> et al.</i>: Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. <i>Science.</i> 2014; <b>343</b>(6168): 301–5. <a target=xrefwindow id=d38673e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/24292625">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1620 href="http://dx.doi.org/10.1126/science.1244851">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4077049">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718194536">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718100766"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1637 class=n-a></a>San Miguel J, Weisel K, Moreau P, <i> et al.</i>: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(11): 1055–66. <a target=xrefwindow id=d38673e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/24007748">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1651 href="http://dx.doi.org/10.1016/S1470-2045(13)70380-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718100766">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725308844"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1664 class=n-a></a>Leleu X, Karlin L, Macro M, <i> et al.</i>: Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood.</i> 2015; <b>125</b>(9): 1411–7. <a target=xrefwindow id=d38673e1675 href="http://www.ncbi.nlm.nih.gov/pubmed/25575538">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1678 href="http://dx.doi.org/10.1182/blood-2014-11-612069">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725308844">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725240115"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1691 class=n-a></a>Morgan G, Palumbo A, Dhanasiri S, <i> et al.</i>: Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. <i>Br J Haematol.</i> 2015; <b>168</b>(6): 820–3. <a target=xrefwindow id=d38673e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/25403264">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1705 href="http://dx.doi.org/10.1111/bjh.13227">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725240115">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726087255"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1718 class=n-a></a>Fouquet G, Pegourie B, Macro M, <i> et al.</i>: Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. <i>Ann Oncol.</i> 2016; <b>27</b>(5): 902–7. <a target=xrefwindow id=d38673e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/26787238">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1732 href="http://dx.doi.org/10.1093/annonc/mdw017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726087255">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d38673e1746 class=n-a></a>Dimopoulos MA, Leleu X, Palumbo A, <i> et al.</i>: Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. <i>Leukemia.</i> 2014; <b>28</b>(8): 1573–85. <a target=xrefwindow id=d38673e1757 href="http://www.ncbi.nlm.nih.gov/pubmed/24496300">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1760 href="http://dx.doi.org/10.1038/leu.2014.60">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4131249">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d38673e1773 class=n-a></a>Rosovsky R, Hong F, Tocco D, <i> et al.</i>: Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>Br J Haematol.</i> 2013; <b>160</b>(3): 351–8. <a target=xrefwindow id=d38673e1784 href="http://www.ncbi.nlm.nih.gov/pubmed/23240658">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1787 href="http://dx.doi.org/10.1111/bjh.12152">Publisher Full Text </a> | <a target=xrefwindow id=d38673e1791 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4114520">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d38673e1800 class=n-a></a>Richardson PG, Schlossman RL, Alsina M, <i> et al.</i>: PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood.</i> 2013; <b>122</b>(14): 2331–7. <a target=xrefwindow id=d38673e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/23950178">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1814 href="http://dx.doi.org/10.1182/blood-2013-01-481325">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718882574"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1823 class=n-a></a>San-Miguel JF, Hungria VT, Yoon SS, <i> et al.</i>: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(11): 1195–206. <a target=xrefwindow id=d38673e1834 href="http://www.ncbi.nlm.nih.gov/pubmed/25242045">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1837 href="http://dx.doi.org/10.1016/S1470-2045(14)70440-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718882574">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725745424"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1850 class=n-a></a>Lokhorst HM, Plesner T, Laubach JP, <i> et al.</i>: Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>N Engl J Med.</i> 2015; <b>373</b>(13): 1207–19. <a target=xrefwindow id=d38673e1861 href="http://www.ncbi.nlm.nih.gov/pubmed/26308596">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1864 href="http://dx.doi.org/10.1056/NEJMoa1506348">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725745424">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725529162"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e1877 class=n-a></a>Lonial S, Dimopoulos M, Palumbo A, <i> et al.</i>: Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>N Engl J Med.</i> 2015; <b>373</b>(7): 621–31. <a target=xrefwindow id=d38673e1888 href="http://www.ncbi.nlm.nih.gov/pubmed/26035255">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1891 href="http://dx.doi.org/10.1056/NEJMoa1505654">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725529162">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d38673e1905 class=n-a></a>Martin T, Richter J, Vij R, <i> et al.</i>: A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAB) As a Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Blood.</i> ASH, 2015; <b>126</b>(23): 509. <a target=xrefwindow id=d38673e1916 href="http://www.bloodjournal.org/content/126/23/509">Reference Source</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d38673e1925 class=n-a></a>Cavo M, Tacchetti P, Patriarca F, <i> et al.</i>: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet.</i> 2010; <b>376</b>(9758): 2075–85. <a target=xrefwindow id=d38673e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/21146205">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1939 href="http://dx.doi.org/10.1016/S0140-6736(10)61424-9">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d38673e1948 class=n-a></a>Moreau P, Avet-Loiseau H, Facon T, <i> et al.</i>: Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Blood.</i> 2011; <b>118</b>(22): 5752–8; quiz 5982. <a target=xrefwindow id=d38673e1959 href="http://www.ncbi.nlm.nih.gov/pubmed/21849487">PubMed Abstract </a> | <a target=xrefwindow id=d38673e1962 href="http://dx.doi.org/10.1182/blood-2011-05-355081">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d38673e1971 class=n-a></a>Durie B, Hoering A, Rajkumar SV, <i> et al.</i>: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. <i>Blood.</i> ASH Annual Meeting Abstracts, 2015; <b>126</b>(23): 25. <a target=xrefwindow id=d38673e1982 href="http://www.bloodjournal.org/content/126/23/25">Reference Source</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d38673e1991 class=n-a></a>Reeder CB, Reece DE, Kukreti V, <i> et al.</i>: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. <i>Leukemia.</i> 2009; <b>23</b>(7): 1337–41. <a target=xrefwindow id=d38673e2002 href="http://www.ncbi.nlm.nih.gov/pubmed/19225538">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2005 href="http://dx.doi.org/10.1038/leu.2009.26">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2711213">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726230355"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2018 class=n-a></a>Moreau P, Hulin C, Macro M, <i> et al.</i>: VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood.</i> 2016; <b>127</b>(21): 2569–74. <a target=xrefwindow id=d38673e2029 href="http://www.ncbi.nlm.nih.gov/pubmed/27002117">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2032 href="http://dx.doi.org/10.1182/blood-2016-01-693580">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726230355">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717950065"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2046 class=n-a></a>Jakubowiak AJ, Dytfeld D, Griffith KA, <i> et al.</i>: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood.</i> 2012; <b>120</b>(9): 1801–9. <a target=xrefwindow id=d38673e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/22665938">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2060 href="http://dx.doi.org/10.1182/blood-2012-04-422683">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717950065">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726055942"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2073 class=n-a></a>Magarotto V, Bringhen S, Offidani M, <i> et al.</i>: Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood.</i> 2016; <b>127</b>(9): 1102–8. <a target=xrefwindow id=d38673e2084 href="http://www.ncbi.nlm.nih.gov/pubmed/26729895">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2087 href="http://dx.doi.org/10.1182/blood-2015-08-662627">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726055942">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725330435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2100 class=n-a></a>Palumbo A, Bringhen S, Mateos MV, <i> et al.</i>: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood.</i> 2015; <b>125</b>(13): 2068–74. <a target=xrefwindow id=d38673e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/25628469">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2114 href="http://dx.doi.org/10.1182/blood-2014-12-615187">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2118 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4375104">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725330435">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d38673e2131 class=n-a></a>Kleber M, Ihorst G, Terhorst M, <i> et al.</i>: Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. <i>Blood Cancer J.</i> 2011; <b>1</b>(9): e35. <a target=xrefwindow id=d38673e2142 href="http://www.ncbi.nlm.nih.gov/pubmed/22829196">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2145 href="http://dx.doi.org/10.1038/bcj.2011.34">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3255252">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d38673e2158 class=n-a></a>Garderet L, Iacobelli S, Moreau P, <i> et al.</i>: Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>J Clin Oncol.</i> 2012; <b>30</b>(20): 2475–82. <a target=xrefwindow id=d38673e2169 href="http://www.ncbi.nlm.nih.gov/pubmed/22585692">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2172 href="http://dx.doi.org/10.1200/JCO.2011.37.4918">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d38673e2181 class=n-a></a>Attal M, Harousseau JL, Stoppa AM, <i> et al.</i>: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. <i>N Engl J Med.</i> 1996; <b>335</b>(2): 91–7. <a target=xrefwindow id=d38673e2192 href="http://www.ncbi.nlm.nih.gov/pubmed/8649495">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2195 href="http://dx.doi.org/10.1056/NEJM199607113350204">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d38673e2205 class=n-a></a>Child JA, Morgan GJ, Davies FE, <i> et al.</i>: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. <i>N Engl J Med.</i> 2003; <b>348</b>(19): 1875–83. <a target=xrefwindow id=d38673e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/12736280">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2219 href="http://dx.doi.org/10.1056/NEJMoa022340">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d38673e2228 class=n-a></a>Fermand JP, Ravaud P, Chevret S, <i> et al.</i>: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. <i>Blood.</i> 1998; <b>92</b>(9): 3131–6. <a target=xrefwindow id=d38673e2239 href="http://www.ncbi.nlm.nih.gov/pubmed/9787148">PubMed Abstract </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718003021"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2248 class=n-a></a>Mellqvist UH, Gimsing P, Hjertner O, <i> et al.</i>: Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. <i>Blood.</i> 2013; <b>121</b>(23): 4647–54. <a target=xrefwindow id=d38673e2259 href="http://www.ncbi.nlm.nih.gov/pubmed/23616624">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2262 href="http://dx.doi.org/10.1182/blood-2012-11-464503">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2266 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3674665">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718003021">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d38673e2279 class=n-a></a>McCarthy PL Jr, Hahn T, Hassebroek A, <i> et al.</i>: Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. <i>Biol Blood Marrow Transplant.</i> 2013; <b>19</b>(17): 1116–23. <a target=xrefwindow id=d38673e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/23660172">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2293 href="http://dx.doi.org/10.1016/j.bbmt.2013.04.027">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2297 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3694566">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d38673e2306 class=n-a></a>Cavo M, Pantani L, Petrucci MT, <i> et al.</i>: Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood.</i> 2012; <b>120</b>(1): 9–19. <a target=xrefwindow id=d38673e2317 href="http://www.ncbi.nlm.nih.gov/pubmed/22498745">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2320 href="http://dx.doi.org/10.1200/JCO.2009.23.7172">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/11494967"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2329 class=n-a></a>Ladetto M, Pagliano G, Ferrero S, <i> et al.</i>: Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. <i>J Clin Oncol.</i> 2010; <b>28</b>(12): 2077–84. <a target=xrefwindow id=d38673e2340 href="http://www.ncbi.nlm.nih.gov/pubmed/20308672">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2343 href="http://dx.doi.org/10.1200/JCO.2009.23.7172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/11494967">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1124445"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2357 class=n-a></a>Paiva B, Vidriales M, Cervero J, <i> et al.</i>: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood.</i> 2008; <b>112</b>(10): 4017–23. <a target=xrefwindow id=d38673e2368 href="http://www.ncbi.nlm.nih.gov/pubmed/18669875">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2371 href="http://dx.doi.org/10.1182/blood-2008-05-159624">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1124445">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725961797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2384 class=n-a></a>Gay F, Oliva S, Petrucci MT, <i> et al.</i>: Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(16): 1617–29. <a target=xrefwindow id=d38673e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/26596670">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2398 href="http://dx.doi.org/10.1016/S1470-2045(15)00389-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725961797">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718556234"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2411 class=n-a></a>Palumbo A, Cavallo F, Gay F, <i> et al.</i>: Autologous transplantation and maintenance therapy in multiple myeloma. <i>N Engl J Med.</i> 2014; <b>371</b>(10): 895–905. <a target=xrefwindow id=d38673e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/25184862">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2425 href="http://dx.doi.org/10.1056/NEJMoa1402888">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718556234">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d38673e2438 class=n-a></a>Attal M, Lauwers-Cances V, Hulin C, <i> et al.</i>: Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood.</i> 2015. <b>126</b>(23): 391. <a target=xrefwindow id=d38673e2449 href="http://www.bloodjournal.org/content/126/23/391?sso-checked=true">Reference Source</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717397804"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2458 class=n-a></a>McCarthy PL, Owzar K, Hofmeister CC, <i> et al.</i>: Lenalidomide after stem-cell transplantation for multiple myeloma. <i>N Engl J Med.</i> 2012; <b>366</b>(19): 1770–81. <a target=xrefwindow id=d38673e2469 href="http://www.ncbi.nlm.nih.gov/pubmed/22571201">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2472 href="http://dx.doi.org/10.1056/NEJMoa1114083">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2476 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3744390">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717397804">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d38673e2489 class=n-a></a>Attal M, Lauwers-Cances V, Marit G, <i> et al.</i>: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. <i>N Engl J Med.</i> 2012; <b>366</b>(19): 1782–91. <a target=xrefwindow id=d38673e2500 href="http://www.ncbi.nlm.nih.gov/pubmed/22571202">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2503 href="http://dx.doi.org/10.1056/NEJMoa1114138">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d38673e2513 class=n-a></a>Rosiñol L, Oriol A, Teruel AI, <i> et al.</i>: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood.</i> 2012; <b>120</b>(8): 1589–96. <a target=xrefwindow id=d38673e2524 href="http://www.ncbi.nlm.nih.gov/pubmed/22791289">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2527 href="http://dx.doi.org/10.1182/blood-2012-02-408922">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718500080"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2536 class=n-a></a>Roussel M, Lauwers-Cances V, Robillard N, <i> et al.</i>: Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. <i>J Clin Oncol.</i> 2014; <b>32</b>(25): 2712–7. <a target=xrefwindow id=d38673e2547 href="http://www.ncbi.nlm.nih.gov/pubmed/25024076">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2550 href="http://dx.doi.org/10.1200/JCO.2013.54.8164">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718500080">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725726306"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2563 class=n-a></a>Palumbo A, Gay F, Cavallo F, <i> et al.</i>: Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>J Clin Oncol.</i> 2015; <b>33</b>(30): 3459–66. <a target=xrefwindow id=d38673e2574 href="http://www.ncbi.nlm.nih.gov/pubmed/26282661">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2577 href="http://dx.doi.org/10.1200/JCO.2014.60.2466">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725726306">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d38673e2590 class=n-a></a>Tricot G, Vesole DH, Jagannath S, <i> et al.</i>: Graft-versus-myeloma effect: proof of principle. <i>Blood.</i> 1996; <b>87</b>(3): 1196–8. <a target=xrefwindow id=d38673e2601 href="http://www.ncbi.nlm.nih.gov/pubmed/8562947">PubMed Abstract </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d38673e2610 class=n-a></a>Krishnan A, Pasquini MC, Logan B, <i> et al.</i>: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncol.</i> 2011; <b>12</b>(13): 1195–203. <a target=xrefwindow id=d38673e2621 href="http://www.ncbi.nlm.nih.gov/pubmed/21962393">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2624 href="http://dx.doi.org/10.1016/S1470-2045(11)70243-1">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2628 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3611089">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d38673e2637 class=n-a></a>Gahrton G, Iacobelli S, Bjorkstrand B, <i> et al.</i>: Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood.</i> 2013; <b>121</b>(25): 5055–63. <a target=xrefwindow id=d38673e2648 href="http://www.ncbi.nlm.nih.gov/pubmed/23482933">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2651 href="http://dx.doi.org/10.1182/blood-2012-11-69452">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/11379956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2661 class=n-a></a>Giaccone L, Storer B, Patriarca F, <i> et al.</i>: Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood.</i> 2011; <b>117</b>(24): 6721–7. <a target=xrefwindow id=d38673e2672 href="http://www.ncbi.nlm.nih.gov/pubmed/21490341">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2675 href="http://dx.doi.org/10.1182/blood-2011-03-339945">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3251223">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/11379956">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/12906956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2692 class=n-a></a>Björkstrand B, Iacobelli S, Hegenbart U, <i> et al.</i>: Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. <i>J Clin Oncol.</i> 2011; <b>29</b>(22): 3016–22. <a target=xrefwindow id=d38673e2703 href="http://www.ncbi.nlm.nih.gov/pubmed/21730266">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2706 href="http://dx.doi.org/10.1200/JCO.2010.32.7312">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/12906956">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d38673e2719 class=n-a></a>Bruno B, Rotta M, Patriarca F, <i> et al.</i>: Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood.</i> 2009; <b>113</b>(14): 3375–82. <a target=xrefwindow id=d38673e2730 href="http://www.ncbi.nlm.nih.gov/pubmed/19064724">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2733 href="http://dx.doi.org/10.1182/blood-2008-07-167379">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2737 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2665903">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d38673e2746 class=n-a></a>Lokhorst HM, Schattenberg A, Cornelissen JJ, <i> et al.</i>: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. <i>J Clin Oncol.</i> 2000; <b>18</b>(16): 3031–7. <a target=xrefwindow id=d38673e2757 href="http://www.ncbi.nlm.nih.gov/pubmed/10944138">PubMed Abstract </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725509450"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2766 class=n-a></a>Noonan KA, Huff CA, Davis J, <i> et al.</i>: Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Sci Transl Med.</i> 2015; <b>7</b>(288): 288ra78. <a target=xrefwindow id=d38673e2777 href="http://www.ncbi.nlm.nih.gov/pubmed/25995224">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2780 href="http://dx.doi.org/10.1126/scitranslmed.aaa7014">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4634889">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725509450">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d38673e2797 class=n-a></a>Rosenblatt J, Glotzbecker B, Mills H, <i> et al.</i>: PD-1 blockade by CT-011, anti-PD-1 antibody, enhances <i>ex vivo</i> T-cell responses to autologous dendritic cell/myeloma fusion vaccine. <i>J Immunother.</i> 2011; <b>34</b>(5): 409–18. <a target=xrefwindow id=d38673e2811 href="http://www.ncbi.nlm.nih.gov/pubmed/21577144">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2815 href="http://dx.doi.org/10.1097/CJI.0b013e31821ca6ce">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3142955">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d38673e2828 class=n-a></a>Garfall AL, Fraietta JA, Maus MV: Immunotherapy with chimeric antigen receptors for multiple myeloma. <i>Discov Med.</i> 2014; <b>17</b>(91): 37–46. <a target=xrefwindow id=d38673e2836 href="http://www.ncbi.nlm.nih.gov/pubmed/24411699">PubMed Abstract </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d38673e2845 class=n-a></a>Rosenblatt J, Vasir B, Uhl L, <i> et al.</i>: Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood.</i> 2011; <b>117</b>(2): 393–402. <a target=xrefwindow id=d38673e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/21030562">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2859 href="http://dx.doi.org/10.1182/blood-2010-04-277137">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2863 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3031474">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d38673e2872 class=n-a></a>Rapoport AP, Aqui NA, Stadtmauer EA, <i> et al.</i>: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. <i>Blood.</i> 2011; <b>117</b>(3): 788–97. <a target=xrefwindow id=d38673e2883 href="http://www.ncbi.nlm.nih.gov/pubmed/21030558">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2886 href="http://dx.doi.org/10.1182/blood-2010-08-299396">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2890 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3035073">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d38673e2899 class=n-a></a>Lacy MQ, Mandrekar S, Dispenzieri A, <i> et al.</i>: Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. <i>Am J Hematol.</i> 2009; <b>84</b>(12): 799–802. <a target=xrefwindow id=d38673e2910 href="http://www.ncbi.nlm.nih.gov/pubmed/19899131">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2913 href="http://dx.doi.org/10.1002/ajh.21560">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2917 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2908015">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d38673e2926 class=n-a></a>Garfall AL, Stadtmauer EA, June CH: Chimeric Antigen Receptor T Cells in Myeloma. <i>N Engl J Med.</i> 2016; <b>374</b>(2): 194. <a target=xrefwindow id=d38673e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/26760100">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2937 href="http://dx.doi.org/10.1056/NEJMc1512760">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/8791956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e2946 class=n-a></a>Benson DM Jr, Bakan CE, Mishra A, <i> et al.</i>: The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. <i>Blood.</i> 2010; <b>116</b>(13): 2286–94. <a target=xrefwindow id=d38673e2957 href="http://www.ncbi.nlm.nih.gov/pubmed/20460501">PubMed Abstract </a> | <a target=xrefwindow id=d38673e2960 href="http://dx.doi.org/10.1182/blood-2010-02-271874">Publisher Full Text </a> | <a target=xrefwindow id=d38673e2964 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3490105">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/8791956">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d38673e2978 class=n-a></a>Lekoshin AM, Ansell SM, Armand P, <i> et al.</i>: Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. <i>Blood.</i> ASH, Abstract, 2014; <b>124</b>(21): 291. <a target=xrefwindow id=d38673e2989 href="http://www.bloodjournal.org/content/124/21/291">Reference Source</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d38673e2998 class=n-a></a>San Miguel J, Mateos MV, Shah JJ, <i> et al.</i>: Pembrolizumab in combination with Lenalidomide and low-dose dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. <i>Blood.</i> ASH, 2015; <b>126</b>(23): 505. <a target=xrefwindow id=d38673e3009 href="http://www.bloodjournal.org/content/126/23/505?sso-checked=true">Reference Source</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d38673e3018 class=n-a></a>Benson DM Jr, Hofmeister CC, Padmanabhan S, <i> et al.</i>: A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood.</i> 2012; <b>120</b>(22): 4324–33. <a target=xrefwindow id=d38673e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/23033266">PubMed Abstract </a> | <a target=xrefwindow id=d38673e3032 href="http://dx.doi.org/10.1182/blood-2012-06-438028">Publisher Full Text </a> | <a target=xrefwindow id=d38673e3036 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3507143">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d38673e3045 class=n-a></a>Shah N, Li L, Kaur I, <i> et al.</i>: Infusion of <i>Ex Vivo</i> Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. <i>Blood.</i> ASH, 2015; <b>126</b>(23): 929. <a target=xrefwindow id=d38673e3059 href="http://www.bloodjournal.org/content/126/23/929?sso-checked=true">Reference Source</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725244212"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e3068 class=n-a></a>Szmania S, Lapteva N, Garg T, <i> et al.</i>: <i>Ex vivo</i>-expanded natural killer cells demonstrate robust proliferation <i>in vivo</i> in high-risk relapsed multiple myeloma patients. <i>J Immunother.</i> 2015; <b>38</b>(1): 24–36. <a target=xrefwindow id=d38673e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/25415285">PubMed Abstract </a> | <a target=xrefwindow id=d38673e3089 href="http://dx.doi.org/10.1097/CJI.0000000000000059">Publisher Full Text </a> | <a target=xrefwindow id=d38673e3092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4352951">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725244212">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d38673e3105 class=n-a></a>Porrata LF, Gertz MA, Inwards DJ, <i> et al.</i>: Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. <i>Blood.</i> 2001; <b>98</b>(3): 579–85. <a target=xrefwindow id=d38673e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/11468153">PubMed Abstract </a> | <a target=xrefwindow id=d38673e3119 href="http://dx.doi.org/10.1182/blood.V98.3.579">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/720322221"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d38673e3129 class=n-a></a>Barlogie B, Mitchell A, van Rhee F, <i> et al.</i>: Curing myeloma at last: defining criteria and providing the evidence. <i>Blood.</i> 2014; <b>124</b>(20): 3043–51. <a target=xrefwindow id=d38673e3140 href="http://www.ncbi.nlm.nih.gov/pubmed/25293776">PubMed Abstract </a> | <a target=xrefwindow id=d38673e3143 href="http://dx.doi.org/10.1182/blood-2014-07-552059">Publisher Full Text </a> | <a target=xrefwindow id=d38673e3147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4231416">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/720322221">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2053.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2053.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA<br/> <sup>2</sup> Division of Hematology/Oncology, University of Cincinnati, Cincinnati, OH, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2053/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 23 Aug 2016, 5:2053 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.8777.1">https://doi.org/10.12688/f1000research.8777.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Dhakal B <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9446 data-id=8777 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8777.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2053/v1/pdf?article_uuid=44422cdb-b353-4c97-ad1a-f6554d56dc35" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.8777.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Dhakal B, Girnius S and Hari P. Recent advances in understanding multiple myeloma [version 1; peer review: 4 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2053 (<a href="https://doi.org/10.12688/f1000research.8777.1" target=_blank>https://doi.org/10.12688/f1000research.8777.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=8777 id=mobile-track-article-signin-8777 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8777?target=/articles/5-2053.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9446 /> <input name=articleId type=hidden value=8777 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Monika Engelhardt</strong>, Department of Hematology and Oncology, University of Freiburg Medical Center, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stefan Knop</strong>, Wilhelm Sander Myeloma Unit, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Qaiser Bashir</strong>, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>David Avigan</strong>, Beth Israel Deaconess Medical Center & Harvard Medical School, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2053.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2053.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16639-15770></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=15621-15772></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16637-15769></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16638-15771></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=4><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2053/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>23 Aug 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Monika Engelhardt</strong>, Department of Hematology and Oncology, University of Freiburg Medical Center, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stefan Knop</strong>, Wilhelm Sander Myeloma Unit, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Qaiser Bashir</strong>, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David Avigan</strong>, Beth Israel Deaconess Medical Center & Harvard Medical School, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2053.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2053/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding multiple...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2053/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2053/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2053/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Dhakal B et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2053/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2053",
            templates : {
                twitter : "Recent advances in understanding multiple myeloma. Dhakal B et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2053/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding multiple myeloma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding multiple myeloma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/8777/9446")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9446");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15769": 0,
                           "15770": 0,
                           "15771": 0,
                           "15772": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d10a6ebf-387c-4e00-a786-3b935fc98d0c";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2053.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2053.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2053.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2053.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2053.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>